Search Result

Results for "

defects

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Autophagy (1) Biochemical Assay Reagents (1) CFTR (2) Cholinesterase (ChE) (1) DNA/RNA Synthesis (2) DYRK (2) Endogenous Metabolite (7) Ephrin Receptor (1) Eukaryotic Initiation Factor (eIF) (1) GSK-3 (1) HDAC (3) IGF-1R (1) Interleukin Related (1) Isotope-Labeled Compounds (1) nAChR (1) NF-κB (1) NO Synthase (1) PD-1/PD-L1 (1) Prostaglandin Receptor (1) PTHR (1) Pyk2 (1) RAD51 (4) TGF-β Receptor (3) Thyroid Hormone Receptor (1) Trk Receptor (1) Wnt (2) β-catenin (1)
By Research Areas:	Cancer (14) Cardiovascular Disease (1) Endocrinology (3) Inflammation/Immunology (10) Metabolic Disease (8) Neurological Disease (11)

By Targets:

Apoptosis (1)

Autophagy (1)

Biochemical Assay Reagents (1)

CFTR (2)

Cholinesterase (ChE) (1)

DNA/RNA Synthesis (2)

DYRK (2)

Endogenous Metabolite (7)

Ephrin Receptor (1)

Eukaryotic Initiation Factor (eIF) (1)

GSK-3 (1)

HDAC (3)

IGF-1R (1)

Interleukin Related (1)

Isotope-Labeled Compounds (1)

nAChR (1)

NF-κB (1)

NO Synthase (1)

PD-1/PD-L1 (1)

Prostaglandin Receptor (1)

PTHR (1)

Pyk2 (1)

RAD51 (4)

TGF-β Receptor (3)

Thyroid Hormone Receptor (1)

Trk Receptor (1)

Wnt (2)

β-catenin (1)

By Research Areas:

Cancer (14)

Cardiovascular Disease (1)

Endocrinology (3)

Inflammation/Immunology (10)

Metabolic Disease (8)

Neurological Disease (11)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-143736

RAD51-IN-5	RAD51	Cancer
RAD51-IN-5 is a potent inhibitor of RAD51. RAD51 is a eukaryote gene. RAD51-IN-5 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2021164746A1, compound 3) .

HY-162258

AChE-IN-57	Cholinesterase (ChE)	Neurological Disease
AChE-IN-57 (compound 5b(SP-2)) is a potent AChE inhibitor. AChE-IN-57 improves cognitive defects. AChE-IN-57 restores the biochemical mediators and inhibits reactive oxygen and nitrogen species implicated in the neuroinflammation mechanism. AChE-IN-57 has the potential for the research of Alzheimer .

HY-162107

Dyrk1A-IN-6	DYRK	Neurological Disease
Dyrk1A-IN-6 (compound 7cc) is an EGCG-like non-competitive inhibitor of DYRK1A. Dyrk1A-IN-6 can be used to alleviate cognitive defects in Down syndrome models .

HY-143737

RAD51-IN-6	RAD51	Cancer
RAD51-IN-6 is a potent inhibitor of RAD51. RAD51 is a eukaryote gene. RAD51-IN-6 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2021164746A1, compound 23) .

HY-143741

RAD51-IN-7	RAD51	Cancer
RAD51-IN-7 is a potent inhibitor of RAD51. RAD51 is a eukaryote gene. RAD51-IN-7 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2021164746A1, compound 71) .

HY-143735

RAD51-IN-4	RAD51	Cancer
RAD51-IN-4 is a potent inhibitor of RAD51. RAD51 is a eukaryote gene. RAD51-IN-4 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2019014315A1, compound R12) .

HY-153189

TrkB-IN-1	Trk Receptor	Neurological Disease
TrkB-IN-1 is a potent and orally active TrkB agonist and has favorable PK properties. TrkB-IN-1 reverses the cognitive defects in an AD mouse model and can be used for alzheimer’s disease research .

HY-B0430B

(±)-Pantothenic acid (±)-Pantothenate; (±)-Vitamin B5	Others	Neurological Disease Metabolic Disease
(±)-Pantothenic acid ((±)-Pantothenate), a B-vitamin, is an essential vitamin required for the biosynthesis of coenzyme A (CoA) in mammalian cells. Pantothenic acid has protective activity against valproic acid (VPA)-induced neural tube defects (NTD) in CD-1 mice .

HY-16637

Folic acid 5+ Cited Publications Vitamin B9; Vitamin M	DNA/RNA Synthesis Endogenous Metabolite	Neurological Disease Cancer
Folic acid (Vitamin B9) is a orally active essential nutrient from the B complex group of vitamins. Folic acid shows antidepressant-like effect. Folic acid sodium reduces the risk of neonatal neural tube defects. Folic acid can be used to the research of megaloblastic and macrocytic anemias due to folic deficiency .

HY-16637A

Folic acid sodium Vitamin B9 sodium; Vitamin M sodium	DNA/RNA Synthesis Endogenous Metabolite	Neurological Disease
Folic acid (Vitamin B9) sodium is a orally active essential nutrient from the B complex group of vitamins. Folic acid sodium shows antidepressant-like effect. Folic acid sodium reduces the risk of neonatal neural tube defects. Folic acid sodium can be used to the research of megaloblastic and macrocytic anemias due to folic deficiency .

HY-P4684

Osteostatin PTHrP (107–111)	PTHR
Osteostatin, a fragment of parathyroid hormone-related protein (PTHrP) 107-111, promotes bone repair in animal models of bone defects and prevents bone erosion in inflammatory arthritis, inhibits collagen-induced arthritis and inhibits osteoclastic bone resorption directly. Osteostatin can be used for inflammation and immunology research .

HY-125021

2BAct 1 Publications Verification	Eukaryotic Initiation Factor (eIF)	Neurological Disease
2BAct is a highly selective, and orally active eIF2B (eukaryotic initiation factor 2B) activator with an EC₅₀ of 33 nM. 2BAct prevents neurological defects caused by a chronic integrated stress response. 2BAct is able to penetrate the central nervous system (CNS). 2BAct displays improved solubility and pharmacokinetics relative to eIF2B activator ISRIB trans-isomer (HY-12495) .

HY-16637D

Folic acid disodium Vitamin B9 disodium; Vitamin M disodium	Endogenous Metabolite	Others Neurological Disease Cancer
Folic acid disodium (Vitamin B9 disodium; Vitamin M disodium) is an orally active disodium salt form of Folic acid (HY-16637) with an intrinsic dissolution rate (IDR) of 4.96·10 ⁵ g/s . Folic acid disodium serves as cofactor in single-carbon transfer reactions and exhibits protective effects against neural tube defects, ischemic events, and cancer. Folate acid disodium overload leads to impaired brain development in embryogenesis and promotes growth of precancerous altered cells. Folic acid deficiency leads to megaloblastic anemia .

HY-122989

Aristolactam BIII	DYRK	Inflammation/Immunology
Aristolactam BIII is a potent DYRK1A inhibitor and inhibits the kinase activity of DYRK1A in vitro (IC₅₀= 9.67 nM. Aristolactam BIII rescues the proliferative defects of DYRK1A transgenic (TG) mouse-derived fibroblasts and neurological and phenotypic defects of DS-like Drosophila models .

HY-19970

KM11060 2 Publications Verification	CFTR Autophagy	Endocrinology
KM11060 is a corrector of the F508 deletion (F508del)-cystic fibrosis transmembrane conductance regulator (CFTR) trafficking defect. KM11060 can be used for the research of F508del-CFTR processing defect and development of cystic fibrosis research .

HY-P4800

Osteostatin (human) Human PTHrP(107-139)	Thyroid Hormone Receptor	Metabolic Disease Inflammation/Immunology
Osteostatin (human), a fragment of parathyroid hormone-related protein (PTHrP) 107-139, promotes bone repair in animal models of bone defects and prevents bone erosion in inflammatory arthritis .

HY-18312

PF-4618433 1 Publications Verification	Pyk2	Metabolic Disease
PF-4618433 is a potent and selective PYK2 inhibitor, with an IC₅₀ of 637 nM. PF-4618433 may be suitable for the research of osteoporosis, craniofacial and appendicular skeletal defects and for targeted bone regeneration .

HY-14839

Evatanepag 2 Publications Verification CP-533536 free acid	Prostaglandin Receptor	Cardiovascular Disease Inflammation/Immunology Endocrinology
Evatanepag (CP-533536) is a non-prostanoid, potent and selective EP₂ receptor agonist. Evatanepag can induce local bone formation in vivo. Evatanepag can be used in the research of fractures, bone defects, asthma .

HY-161464

Chlopynostat	HDAC Apoptosis	Cancer
Chlopynostat (Compound 6c) is a HDAC1 inhibitor with a IC₅₀ value of 67 nM. Chlopynostat reverses STAT4/p66Shc defects by inhibiting HDAC1-induced < b>Apoptosis .

HY-144655

IP2	Others	Cancer
IP2 is an immunomodulatory agent. IP2 increases PTP (Pioneer Translation Product)-derived antigen presentation in cancer cells. IP2 shows non-cytotoxic for cancer cells. IP2 induces tumor growth defects in mouse .

HY-108905

Mecasermin Human IGF-I; FK 780	IGF-1R	Metabolic Disease
Mecasermin (Human IGF-I; FK 780) is a recombinant human insulin-like growth factor I (IGF-I). Mecasermin has the potential for the study of the growth failure of growth hormone (GH) insensitivity caused by GH receptor defects or GH-inhibiting antibodies .

HY-113365

Cholestenone 4-Cholesten-3-one	Endogenous Metabolite	Metabolic Disease
Cholestenone (4-Cholesten-3-one), the intermediate oxidation product of cholesterol, is metabolized primarily in the liver. Cholestenone is highly mobile in membranes and influences cholesterol flip-flop and efflux. Cholestenone may cause long-term functional defects in cells .

HY-158223

Carboxymethyl chitosan Methacryloyl CMCSMA	Biochemical Assay Reagents	Others
Carboxymethyl chitosan Methacryloyl (CMCSMA) is methacrylated carboxymethyl chitosan with properties as a 3D printing ink. A composite hydrogel made of Carboxymethyl chitosan Methacryloyl can effectively accelerate bone healing in an infectious microenvironment after implantation in a rat model of Staphylococcus aureus-infected femoral defect .

HY-163172

Miro1 Reducer	Others	Neurological Disease
Miro1 Reducer is a small molecule that can repair this defect of Miro1 in Parkinson's disease (PD) fibroblasts. Miro1 Reducer reduces the delayed mitophagy phenotype in PD fibroblasts. Miro1 Reducer reduces Miro1 protein levels in dose-dependent manner (IC₅₀ = 7.8 mM) .

HY-161465

HDAC8-IN-7	HDAC	Inflammation/Immunology
HDAC8-IN-7 (H7E), a HDAC8 inhibitor, exerts retinoprotective effects against glaucomatous injury via ameliorating aberrant Müller glia activation and oxidative stress. HDAC8-IN-7 alleviates functional and structural defects within the inner retina .

HY-157958

α7 nAChR Modulator-3	nAChR	Neurological Disease
α7 nAChR modulator-3 (Compound 6p) is a α7 nAChR positive allosteric Modulator with a IC₅₀ value of 1.3 μM. α7 nAChR Modulator-3 can be used to inhibit auditory gating defects in a mouse schizophrenic model .

HY-113365S

Cholestenone-d5 4-Cholesten-3-one-d₅	Endogenous Metabolite
Cholestenone-d₅ is the deuterium labeled Cholestenone. Cholestenone (4-Cholesten-3-one), the intermediate oxidation product of cholesterol, is metabolized primarily in the liver. Cholestenone is highly mobile in membranes and influences cholesterol flip-flop and efflux. Cholestenone may cause long-term functional defects in cells[1][2][3].

HY-113365S1

Cholestenone-13C 4-Cholesten-3-one-¹³C	Endogenous Metabolite
Cholestenone- ¹³C is the ¹³C labeled Cholestenone. Cholestenone (4-Cholesten-3-one), the intermediate oxidation product of cholesterol, is metabolized primarily in the liver. Cholestenone is highly mobile in membranes and influences cholesterol flip-flop and efflux. Cholestenone may cause long-term functional defects in cells[1][2][3].

HY-113365S2

Cholestenone-13C2 4-Cholesten-3-one-¹³C₂	Isotope-Labeled Compounds Endogenous Metabolite
Cholestenone- ¹³C₂ is the ¹³C labeled Cholestenone. Cholestenone (4-Cholesten-3-one), the intermediate oxidation product of cholesterol, is metabolized primarily in the liver. Cholestenone is highly mobile in membranes and influences cholesterol flip-flop and efflux. Cholestenone may cause long-term functional defects in cells[1][2][3].

HY-117709

BRD6688	HDAC	Neurological Disease
BRD6688 is a selective HDAC2 inhibitor. BRD6688 increases H4K12 and H3K9 histone acetylation in primary mouse neuronal cells. BRD6688 crosses the blood brain barrier and rescues the memory defects associated with p25 induced neurodegeneration in contextual fear conditioning in a CK-p25 mouse model .

HY-P2264

KYL peptide	Ephrin Receptor	Inflammation/Immunology
KYL peptide, an antagonistic peptide, selectively targets EphA4 receptor (IC₅₀:4.22 μM, Kd:1.3 μM). KYL peptide binds to the ligand-binding domain of EphA4, effectively alleviates Aβ-induced synaptic dysfunction and synaptic plasticity defects in AD mice. KYL peptide can promote nerve regeneration after injury and modulating immune responses .

HY-155705

BMP agonist 1	TGF-β Receptor GSK-3 β-catenin	Others
BMP agonist 1 (compound 2 b) is a small-molecule agonist of bone morphogenic protein (BMP). BMP induces C2C12 cell differentiation with BMP and highly depends on active BMP signaling. BMP agonist 1 inhibits GSK3β, increases β-catenin signaling and synergistically regulates Id2and Id3 expression. BMP agonist 1 is used in diseases and defects of the skeleton research .

HY-19987

BML-284 Maximum Cited Publications 23 Publications Verification	Wnt	Cancer
BML-284 is a potent and cell-permeable Wnt signaling activator. BML-284 induces TCF-dependent transcriptional activity with an EC₅₀ of 700 nM .

HY-19987A

BML-284 hydrochloride	Wnt	Cancer
BML-284 hydrochloride is a potent and cell-permeable Wnt signaling activator. BML-284 induces TCF-dependent transcriptional activity with an EC₅₀ of 700 nM .

HY-N1445

Isoquercetin 1 Publications Verification Quercetin 3-glucoside	NF-κB NO Synthase	Inflammation/Immunology Cancer
Isoquercetin (Quercetin 3-glucoside) is a naturally occurring polyphenol that has antioxidant, anti-proliferative, and anti-inflammatory properties. Isoquercetin alleviates ethanol-induced hepatotoxicity, oxidative stress, and inflammatory responses via the Nrf2/ARE antioxidant signaling pathway . Isoquercetin regulates the expression of nitric oxide synthase 2 (NO2) via modulating the nuclear factor-κB (NF-κB) transcription regulation system. Isoquercetin has high bioavailability and low toxicity, is a promising candidate agent to prevent birth defects in diabetic pregnancies .

HY-103369

PG01	CFTR	Endocrinology
PG01 is a potent CFTR Cl ^- channel potentiator. PG01 can correct gating defects of CFTR mutants, is effective on b>E193K, G970R and G551D (CFTR mutants) with K_d values of 0.22 μM, 0.45 μM and 1.94 μM, respectively. PG01 is also effective on ΔF508 (K_a of 0.3 μM). PG01 increases ΔF508-CFTR Cl ^- current after adding Forskolin .

HY-145769

N2S2-CBMBC	PD-1/PD-L1	Cancer
N2S2-CBMBC, an N2S2 bromo-benzyl ether derivative, acts as a ligand and use ^99mTc-labelled complexes ^99mTc-N2S2-CBMBC can be used as an imaging agent to be applied to the aspect of detecting PD-L1 expression, realize the real-time, comprehensive and convenient detection of the PD-L1 level of tumors, and overcome the defects of an immunohistochemical method .

HY-P0299A

LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA) 5+ Cited Publications	TGF-β Receptor	Cancer
LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) TFA can readily crosse the blood-brain barrier .

HY-P0299

LSKL, Inhibitor of Thrombospondin (TSP-1) 5+ Cited Publications	TGF-β Receptor	Cancer
LSKL, Inhibitor of Thrombospondin (TSP-1) is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) can readily crosse the blood-brain barrier .

HY-N0976

1,11b-Dihydro-11b-hydroxymedicarpin 11b-Hydroxy-11b,1-dihydromedicarpin	Interleukin Related	Inflammation/Immunology
1,11b-Dihydro-11b-hydroxymedicarpin (11b-Hydroxy-11b,1-dihydromedicarpin) is a pterocarpan from Ononis viscosa subsp. breviflora is a Medicarpin derivative . Medicarpin, a natural pterocarpan, heals cortical bone defect by activation of Notch and Wnt canonical signaling pathways . Medicarpin prevents arthritis in post-menopausal conditions by arresting the expansion of TH17 cells and pro-inflammatory cytokines. Medicarpin down-regulates pro-inflammatory cytokines like TNF-α, IL-6 and IL-17A, while up-regulates anti-inflammatory cytokine IL-10 in arthritis (CIA) model of mice .

Cat. No.	Product Name

HY-L054

Endoplasmic Reticulum Stress Compound Library	221 compounds
Endoplasmic reticulum (ER) contributes to the production and folding of approximately one third of cellular proteins, and is thus inextricably linked to the maintenance of cellular homeostasis and the fine balance between health and disease. However, some adverse factors negatively impact ER functions and protein synthesis, resulting in the activation of Endoplasmic reticulum stress (ER stress, ERS) and unfolded protein response (UPR) signaling pathways. The UPR is triggered when ER protein folding capacity is overwhelmed by cellular demand and the UPR initially aims to restore ER homeostasis and normal cellular functions. However, if this fails, then the UPR triggers cell death. Chronic ER stress and defects in UPR signaling are emerging as key contributors to a growing list of human diseases, including diabetes, neurodegeneration and cancer. MCE Endoplasmic Reticulum Stress Compound Library contains 221 ER stress-related compounds that mainly target PERK, IRE1, ATF6, etc. MCE ER stress library is a useful tool for researching ER stress and related diseases.

Endoplasmic Reticulum Stress Compound Library

221 compounds

Endoplasmic reticulum (ER) contributes to the production and folding of approximately one third of cellular proteins, and is thus inextricably linked to the maintenance of cellular homeostasis and the fine balance between health and disease. However, some adverse factors negatively impact ER functions and protein synthesis, resulting in the activation of Endoplasmic reticulum stress (ER stress, ERS) and unfolded protein response (UPR) signaling pathways. The UPR is triggered when ER protein folding capacity is overwhelmed by cellular demand and the UPR initially aims to restore ER homeostasis and normal cellular functions. However, if this fails, then the UPR triggers cell death. Chronic ER stress and defects in UPR signaling are emerging as key contributors to a growing list of human diseases, including diabetes, neurodegeneration and cancer.

MCE Endoplasmic Reticulum Stress Compound Library contains 221 ER stress-related compounds that mainly target PERK, IRE1, ATF6, etc. MCE ER stress library is a useful tool for researching ER stress and related diseases.

HY-L018

TGF-beta/Smad Compound Library	226 compounds
The transforming growth factor beta (TGF-β) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins (BMPs), activins and related proteins. Signaling begins with the binding of a TGF beta superfamily ligand to a TGF beta type II receptor. The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the Type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD (e.g. SMAD4). R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Deregulation of TGF-β signaling contributes to developmental defects and human diseases, including cancers, some bone diseases, chronic kidney disease, etc. MCE designs a unique collection of 226 TGF-beta/Smad signaling pathway compounds. TGF-beta/Smad Compound Library acts as a useful tool for TGF-beta/Smad-related drug screening and disease research.

TGF-beta/Smad Compound Library

226 compounds

The transforming growth factor beta (TGF-β) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins (BMPs), activins and related proteins. Signaling begins with the binding of a TGF beta superfamily ligand to a TGF beta type II receptor. The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the Type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD (e.g. SMAD4). R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Deregulation of TGF-β signaling contributes to developmental defects and human diseases, including cancers, some bone diseases, chronic kidney disease, etc.

MCE designs a unique collection of 226 TGF-beta/Smad signaling pathway compounds. TGF-beta/Smad Compound Library acts as a useful tool for TGF-beta/Smad-related drug screening and disease research.

Carboxymethyl chitosan Methacryloyl CMCSMA	3D Bioprintig
Carboxymethyl chitosan Methacryloyl (CMCSMA) is methacrylated carboxymethyl chitosan with properties as a 3D printing ink. A composite hydrogel made of Carboxymethyl chitosan Methacryloyl can effectively accelerate bone healing in an infectious microenvironment after implantation in a rat model of Staphylococcus aureus-infected femoral defect .

Cat. No.	Product Name	Target	Research Area